ArticleDiabetes2026
cGAS-STING Pathway Mediates Retinal Pigmental Epithelial Dysfunction in Diabetic Retinopathy.
Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetic retinopathy (DR) is a predominant cause of vision impairment among working-age individuals, with a subset of patients responding poorly to current treatments. This study investigated alterations in double-stranded DNA (dsDNA) levels in the aqueous humor and retinal pigment epithelium (RPE) dysfunction in DR patients, exploring the potential role of the cyclic GMP-AMP synthase (cGAS)-STING pathway in DR progression. We found that DR patients showed significantly elevated dsDNA levels in the aqueous humor compared with control individuals. Fundus autofluorescence imaging revealed an increase in high-autofluorescence spots in DR patients, indicating early RPE dysfunction. In vivo and in vitro models of DR demonstrated mitochondrial damage and dsDNA leakage in RPE cells, along with cGAS-STING pathway activation in the retina. Pharmacological inhibition of STING reduced cytoplasmic dsDNA accumulation and damaged mitochondria, alleviating inflammation in vitro. In vivo, STING inhibition ameliorated RPE dysfunction and vascular changes. These findings highlight the critical role of the cGAS-STING pathway in DR pathogenesis and suggest that STING inhibition may serve as a promising therapeutic strategy to reduce retinal inflammation and slow the progression of DR. ARTICLE HIGHLIGHTS: The retinal pigment epithelium (RPE) serves as the outer blood-retinal barrier, protecting the neural retina from systemic changes. We aimed to preserve RPE integrity through early intervention and inhibit DR progression. Our study focused on determining whether the involvement of the cyclic GMP-AMP synthase-STING pathway and mitochondrial damage drive RPE dysfunction. We found that mitochondrial dysfunction in the RPE under diabetic conditions triggers activation of the cyclic GMP-AMP synthase-STING pathway, leading to disruption of RPE and retinal vascular instability. Targeting this pathway restored RPE function and limited retinal deterioration. These findings highlight a promising therapeutic approach for preventing disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.